Development and Validation of UV-Visible Spectrophotometric method for simultaneous estimation of Etoposide and Picroside-II in bulk and pharmaceutical formulation
Abstract
Aim: To develop and validate a simple, precise, accurate, and sensitive UV-visible spectrophotometric method for the simultaneous estimation of Etoposide (ETO) and Picroside-II (PK-II) in a bulk and pharmaceutical formulation according to the ICH guidelines.
Methods: The absorption spectra of ETO and PK-II were carried out over the range of 200-800 nm, and absorption maxima were determined. Multiple calibration standards were prepared of both the drugs separately, and absorbance were recorded at respective λmax. Calibration curve were plotted and the linear responses were studied. Various analytical method validation parameters viz. accuracy, precision, LOD, LOQ, robustness and ruggedness were calculated using QC standards.
Results: The absorption maxima of ETO and PK-II were found to be 208 nm and 265 nm respectively. Linearity range for ETO and PK-II were found to be 1-7 μg/ml and 1-35 μg/ml with correlation coefficient 0.999 and 0.999. The intra-day and inter-day study shows percent relative standard deviation in between 0.11 to 1.08 and 0.12 to 1.38. LOD and LOQ were found to be 0.1321 μg/ml and 0.4003 μg/ml for ETO whereas 0.1616μg/ml and 0.4897μg/ml for PK-II. The total percent recovery of ETO and PK-II were found to be 99.09 and 99.68 respectively.
Conclusion: The simple, precise, accurate, and sensitive UV-visible spectrophotometric method for the simultaneous estimation of Etoposide (ETO) and Picroside-II (PK-II) in a bulk and pharmaceutical formulation was developed and validated.
Keywords: UV-visible spectrophotometry, simultaneous estimation, Etoposide and Picroside-II.
Downloads
References
2. Peter I. Clark, Maurice L. Slevin, The Clinical Pharmacology of Etoposide and Teniposide, Clinical pharmacokinetics, 1987; 12(4):223-252.
3. David G. Bailey,Fruit juice inhibition of uptake transport: a new type of food–drug interaction. British Journal of Clinical Pharmacology, 2010; 70(5):645-655.
4. Jose Luis Aguilar Ponce, Yolanda Flores-Picazo, Jose Perez-Urizar, Gilberto Castrieda-Hernández, Juan W. et.al. Bioavailability of Etoposide after Oral Administration of the Solution Marketed for Intravenous Use: Therapeutic and Pharmacoeconomic Perspectives, Archives of Medical Research, 1999; 3:212–215.
5. V. J. Harvey, M. L. Slevin, S. P. Joel, M. M. Smythe, A. Johnstons and P. F. M. Wrigley. Variable Bioavailability Following Repeated Oral Doses of Etoposide, European Journal of Cancer and Clinical Oncology, 1985; 21(2):1315-1319.
6. Desmond N. Carney, MD, The Pharmacology of Intravenous and Oral Etoposide, Cancer, 1991; 67(S1):299-302.
7. Ishtiyaq Ahmad Najar,Rakesh Kamal Johri, Pharmaceutical and Pharmacological approaches for Bioavailability Enhancement of Etoposide, Journal of Biosciences, 2014; 39(1):139-144.
8. Ayyapan T, Shanmugham S, Vetrichelvan T, Response design optimized polymeric nanoparticles of etoposide for improved oral bioavailability in albino rats, Research Journal of Pharmacy and Pharmacology, 2018; 11(6):2538-2540.
9. Parveen Kumar, Lubna Wasim, Madhu Chopra, Aruna Chhikara, Co-delivery of Vorinostat and Etoposide Via Disulfide Cross-Linked Biodegradable Polymeric Nanogels: Synthesis, Characterization, Biodegradation, and Anticancer Activity, AAPS PharmSciTech, 2018; 19(2):634-647.
10. Ahmed A. Abdulhussein Al-Alia, Jeffrey Rong Chao Quachb, et.al.Polysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-Dawley rats, International Journal of Pharmaceutics, 2018; 543(1-2):352-360.
11. Nanjwade Basavaraj K, Hiremath, Gurudev M, et.al, Formulation and Evaluation of Etoposide Loaded Aquasomes, Journal of Nanopharmaceutics and Drug Delivery, 2013; 1:92-101.
12. Nayab Khalid, Muhammad Sarfraz1, Mosab Arafat et.al, Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs,Journal of Pharmaceutical Sciences, 2018; 21:398-408.
13. Wakte P., Patil A., Bhusari S., Quazi M., Jabde S., Shinde D., Optimization of microwave-assisted extraction for picroside I and picroside II from Picrorrhizakurroa using Box-Behnken experimental design. Frontiers of chemical science and engineering, 2014; 8(4):445–453.
14. Bhusari SS. IND, Patent No. 201721000684(27.Jan.2017).
15. Note for guidance on validation of analytical procedures: text and methodology. European Medicines Agency: 1995; 1-15.
16. Validation of analytical procedures: text and methodology q2 (r1). ICH harmonised tripartite guideline, (1994).
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.